SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Coming soon · Friday 13 November · 09:45 CET

The International Lung Cancer Summit 2026

Live Summit5 + 5 CME credits · EACCME & SSMO

Event details

The International Lung Cancer Summit 2026

Led by global experts

The people in the room

A global roster of oncologists, surgeons and pathologists — chaired from Lausanne, drawn from across the field.

Solange Peters

Chair, Switzerland

Alfredo Addeo

Chair, Switzerland

Millie Das

USA

Hidehito Horinouchi

Japan

Telma Sequeira

Portugal

Christine Lovly

USA

David Planchard

France

Sandip Patel

USA

Alessio Cortellini

Italy

Lauren Byers

USA

Giannis Mountzios

Greece

Anne-Marie Dingemans

Netherlands

The programme · 13 Nov 2026

The day, hour by hour

The full running order — every session, its time, and who is giving it.

Morning 09:45 – 12:30
09:45

Welcome & introduction

Peters & Addeo · chairs
09:50

ctDNA-guided decisions in lung cancer: ready or not?

Millie Das
10:10

New standards in EGFR- and ALK-positive NSCLC

Hidehito Horinouchi
10:35

Other actionable genomic alterations, incl. HER2 and ROS1

Telma Sequeira
11:00Open discussion & coffee break
11:15

Targeting (K)RAS with new compounds

Christine Lovly
11:50

The ADC wave: integrating new agents in NSCLC

David Planchard
12:30Industry satellite symposia
Afternoon 14:15 – 17:00
14:15

Latest options in early-stage NSCLC: novel IO approaches for improved outcomes

Sandip Patel
14:40

New compounds and combinations for non-oncogene-addicted advanced NSCLC

Alessio Cortellini
15:15Open discussion & coffee break
15:30

The emerging role of T-cell engagers and ADCs in SCLC

Lauren Byers
16:35

Panel · open questions & patient cases

All speakers & attendees
17:00

Closing remarks

Peters & Addeo · chairs
Industry satellite symposia
12:30

Programme to be announced

13:00

Programme to be announced

Where we meet · Lausanne

On site & online

Hosted at CHUV in Lausanne and live-streamed worldwide — join in person, or from your own clinic.

VenueCHUV · Fondation ISREC · Bâtiment AGORA
AddressRue du Bugnon 25A, 1005 Lausanne
DateFri 13 Nov 2026 · 09:45 CET
FormatHybrid · live-streamed · CME-certified

ILCS · In frames

Last year, in Lausanne

A day on the ground — faculty, debate and the room between sessions.

       Continue With

Related Topics

Sep 09 2026
IMMUNOTHERAPIES
Advanced NSCLCImmunotherapies

HARMONi primary analysis reports 6.8 against 4.4 months PFS for ivonescimab plus chemotherapy after EGFR TKI progression

Read the article

Sep 08 2026
IMMUNOTHERAPIES
Advanced NSCLCImmunotherapies

Pleural metastases carried worse two-year survival than contralateral lung metastases in stage M1a NSCLC

Read the article

L. Hendriks
Sep 04 2026
TARGETED THERAPIES
Advanced NSCLCTargeted Therapies

An EGFR-SHC1 fusion resists EGFR inhibitors through its non-kinase partner

Read the article

X. Le
Sep 03 2026
IMMUNOTHERAPIES
Advanced NSCLCImmunotherapies

Akeso reports an OS benefit for ivonescimab over pembrolizumab in PD-L1-positive NSCLC

Read the article

Sep 02 2026
IMMUNOTHERAPIES
Advanced NSCLCImmunotherapies

AI-HOPE registry recruits 920 patients to build machine-learning models for metastatic NSCLC outcomes

Read the article

R. FerraraL. Hendriks
Aug 31 2026
TARGETED THERAPIES
Resectable NSCLCTargeted Therapies

Adjuvant alectinib held its advantage in ALINA’s Asia subgroup, on 31 events and immature survival data

Read the article

H. Horinouchi
Aug 29 2026
ADCs
Advanced NSCLCADCs

International panel sets 55 consensus recommendations for managing Dato-DXd side effects in NSCLC

Read the article

S. Saw
Aug 27 2026
ADCs, IMMUNOTHERAPIES, TARGETED THERAPIES
Advanced NSCLCADCsImmunotherapies

Two EORTC questionnaires cover the common side effects in NSCLC labels, and miss 62 rarer ones

Read the article

J. RemonR. Ferrara
Aug 25 2026
TARGETED THERAPIES
Resectable NSCLCTargeted Therapies

Fewer patients discontinued adjuvant alectinib than chemotherapy in ALINA, and quality-of-life gains held to two years

Read the article

M. HochmairH. HorinouchiD. Planchard
Aug 25 2026
IMMUNOTHERAPIES
Advanced NSCLCBiomarkersImmunotherapies

Cleared ctDNA within weeks predicted longer survival on immunotherapy in a 109-patient study

Read the article

P. Forde
Aug 23 2026
Biomarkers, SCLC
BiomarkersSCLC

SLFN11 expression across lung neuroendocrine neoplasms: highest in SCLC, and prognostic only there

Read the article

A. Dingemans
Aug 21 2026
IMMUNOTHERAPIES
Advanced NSCLCBiomarkersImmunotherapies

A ctDNA tumour fraction of 5 percent or more marks the patients who benefit from adding chemotherapy to checkpoint blockade

Read the article

D. Planchard
Aug 19 2026
IMMUNOTHERAPIES
BiomarkersResectable NSCLCImmunotherapies

AIOT expert panel endorses chemo-immunotherapy as a new standard in resectable stage II-III NSCLC

Read the article

T. CasconeP. FordeA. Passaro
Aug 13 2026
IMMUNOTHERAPIES
BiomarkersResectable NSCLCImmunotherapies

Pre-surgical ctDNA clearance reached 66% with neoadjuvant nivolumab against 38% with placebo in CheckMate 77T

Read the article

T. Cascone
Charles Rudin
Aug 09 2026
IMMUNOTHERAPIES
Advanced NSCLCImmunotherapies

Radiation plus durvalumab without chemotherapy cleared its survival target in frail LA-NSCLC patients

Read the article

C. Rudin
Aug 08 2026
TARGETED THERAPIES
Advanced NSCLCBiomarkersTargeted Therapies

EGFR amplification at baseline marks shorter time on first-line osimertinib, in exon 19 deletions but not L858R

Read the article

B. Ricciuti
Aug 07 2026
ADCs
Advanced NSCLCBiomarkersADCs

EVOKE-01 biomarker analysis: Trop-2 staining did not pick out who does better on sacituzumab govitecan than docetaxel

Read the article

G. Mountzios
Aug 06 2026
TARGETED THERAPIES
Advanced NSCLCTargeted Therapies

ORCHARD final data: osimertinib plus gefitinib gives modest benefit in EGFR C797X, and the authors advise against further study

Read the article

X. LeZ. Piotrowska
Aug 06 2026
TARGETED THERAPIES
Resectable NSCLCTargeted Therapies

Adjuvant crizotinib did not prolong DFS in resected ALK-positive NSCLC

Read the article

J. Sands
Solange Peters
Aug 05 2026
IMMUNOTHERAPIES
Advanced NSCLCImmunotherapies

AdvanTIG-301 closed early with 63 patients, leaving its stage III NSCLC comparisons descriptive

Read the article

S. Peters